US Pharma MarketingThe results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
Source: BioPharma Dive